ASH2023 - Sheba 2.0, page-124

RC220 was designed not only to provide the ability to be delivered via a peripheral vein, but also provide identical pharmacokinetics to RC110. While Race has to start at Phase 1 for any new applications (such as FTO or cardioprotection), the process of dose optimisation can proceed much faster because all of the historical data around RC110.

The major advanatage of RC220 is it resets the patent clock for Bisantrene and provides IP protection outside of the orphan drug indication setting.

What I like most about RC220 is you get all the IP benefit of having a new drug, but you know it is going to work in humans. A close analogy to RC220 is the reformulation of paclitaxel to make Abaxane. You might want to investigate how much Celgene paid to buy Abraxane.